Custom designing therapeutic cancer vaccines. Delivery of immunostimulatory molecule adjuvants by protein transfer

Human Vaccines

Volumn 4, Issue 5, 2008, Pages 384-388

  Selvaraj, Periasamy ^a   Yerra, Archana ^b   Tien, Linda ^a   Shashidharamurthy, Rangaiah ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ANNA UNIVERSITY   (India)

Author keywords

Cancer vaccines; CD80; Dendritic cells; GPI anchor; Immunotherapy; Membrane vaccine; Protein transfer

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOMODULATING AGENT; PEPTIDE VACCINE; PROTEIN; TUMOR ANTIGEN; VIRUS VECTOR;

ADJUVANT THERAPY; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER CELL; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RECURRENCE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL BASED GENE THERAPY; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DNA RECOMBINATION; DRUG DESIGN; DRUG POTENCY; DRUG PURIFICATION; EX VIVO STUDY; GENETIC TRANSFECTION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NOTE; REGULATORY T LYMPHOCYTE; THERAPY DELAY; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM;

EID: 54949131327     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.5.5866     Document Type: Note

References (60)

1. Nemunaitis J, Sterman D, Jablons D, Smith JWII, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, Hege K. Granulocyte-Macrophage colony-stimulating factor gene-modified autologous tumor vaccines in nonsmall-cell lung cancer. JNCI 2004; 96:326.
2. Dunn GP, Old LP, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329.
3. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14:483.
4. Elliot BE, Carlow DA, Rodricks A, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 1989; 53:181.
5. Ostrand Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after tranfection of MHC Class II Genes. J Immunol 1990; 144:4068.
6. Ward R, Kaufman HL. Targeting Costimulatory Pathways for Tumor Immunotherapy. Int Rev Immunol 2007; 26:161.
7. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211:214.
8. barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682.
9. Pulendran B, Ahmed R. Translating innate immunity into immunological memory:implications for vaccine development. Cell 2006; 124:849.
10. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121:1.
11. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195.
12. Chattopadhyay S, Chakraborty NG. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005; 54:1153.
13. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunther 2006; 28:120.
14. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167.
15. Pulendran B, Maraskovsky E, Banchereau J, Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends in Immunology 2001; 22:41.
16. Torre Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. A highly immunogenic tumor transfected with murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87:1486.
17. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328.
18. Heaton KM, Grimm, EA. Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol Immunother 1993; 37:213.
19. Pardoll DM. Paracrine Cytokine Adjuvants in Cancer Immunotherapy. Annu Rev Immunol 1995; 13:399.
20. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1995; 1:1179.
21. Tuting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD, Storkus WJ. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Therapy 1999; 6:73.
22. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in adaptive world. Immunity 1998; 8:657.
23. Yamazaki K, Nguyen T, Podack ER. Tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol 1999; 163:5178.
24. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy M. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994; 263:518.
25. + T cells by B7-transfected melanoma cells. Science 1993; 259:368.
26. Sharpe AH, Freeman GJ. The B7 - CD28 superfamily. Nature Rev Immunol 2002; 2:116.
27. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264:961.
28. Wu TC, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995; 182:1415.
29. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 Expression Confer Antigen-presenting cell capacity to tumours in vivo? J Exp Med 1996; 183:769.
30. Davis HL, Demeneix BA, Quantin B, Coulombe J, Whalen RG, Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum Gene Ther 1993; 4:733.
31. Verma I, Somia N. Gene therapy-promises, problems and prospects. Nature 2007; 389:239.
32. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-XI. Science 2003; 302:415.
33. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Hum Gene Ther 1997; 57:1537.
34. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995; 92:8078.
35. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18:245.
36. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50:507.
37. McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P. Construction, purification and functional reconstitution on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 1995; 92:8059.
38. Udenfriend S, Kodukula K. How glycosyl phospharidylinositol-anchored membrane proteins are made. Annu Rev Biochem 1995; 64:563.
39. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor(DAF) into their membranes. J Exp Med 1984; 160:1558.
40. Selvaraj P, Dustin ML, Silber R, Low MG, Springer TA. Deficiency of lymphocyte function associated antigen-3 (LFA-3) in Paroxysmal Nocturnal Hemoglobinuria: Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med 1987; 166:1011.
41. Nagarajan S, Anderson M, Ahmed SN, Sell KW, Selvaraj P. Purification and optimization of functional reconstitution on the surface of leukemic cell lines of GPI-anchored Fc gamma receptor III. J Immunol Methods 1995; 184:241.
42. Selvaraj P, Plunkett ML, Dustin ML, Sanders ME, Shaw S, Springer TA. The T-lymphocyte glycoprotein CD2 binds the cell surface ligand. Nature 1987; 326:400.
43. Selvaraj P, Rosse WF, Silber R, Springer TA. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal hemoglobinuria. Nature 1988; 333:565.
44. Nagarajan S, Selvaraj P. Reconstitution of CD16 expression on nucleated cells using purified CD16. FASEB J 1991; 5:1718.
45. Low MG. The glycosyl-phosphatidylinositol achor of membrane proteins. Biochim Biophys Acta 1989; 988:427.
46. Waneck GL, Stein ME, Flavell RA. Conversion of a PI-anchored protein to an integral membrane protein by a single amino acid mutation. Science 1988; 241:697.
47. Caras IW, Weddell GN, Davitz MA, Nussenzweig V, Martin DW Jr. Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science 1987; 238:1280.
48. Tykocinski ML, Shu HK, Ayers DJ, Walter EI, Getty RR, Groger RK, Hauer CA, Medof ME. Glycolipid reanchoring of T-lymphocyte surface antigen CD8 using the 3′ end sequence of decay-accelerating factor's mRNA. Proc Natl Acad Sci USA 1988; 85:3555.
49. Poloso NJ, Nagarajan S, Mejia Oneta JM, Selvaraj P. GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine. Molecular Immunol 2002; 38:803.
50. McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P. Construction, purification, and functional reconstitution on tumor cells of a glycolipid anchored B7-1 molecule: A novel alternative to gene transfection in human immunotherapy. Proc Amer Assoc Cancer Res 1995; 36:494.
51. Poloso N, Nagarajan S, Bumgarner GW, Selvaraj P. Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine 2001; 19:2029.
52. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol 1995; 155:5498.
53. Wang YC, Zhu L, McHugh R, Graham Jr SD, Hillyer CD, Dillehay D, Sell KW, Selvaraj P. Induction of Autologous tumor-specific cytotoxic T-lymphocyte activity against a Human Renal Carcinoma Cell Line by B7-1 (CD80) costimulation. J Immunother 1996; 19:1.
54. McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. Protein transfer of glycosylphosphatidylinositol-B7-1 into tumor cell membranes: A novel approach to tumor immunotherapy. Cancer Res 1999; 59:2433.
55. Huang JH, Getty RR, Chisari FV, Fowler P, Greenspan NS, Tykocinski ML. Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. Immunity 1994; 1:607.
56. Liu S, Foster BA, Chen T, Zheng G, Chen A. Modifying Dendritic Cells via Protein Transfer for Antitumor Therapeutics. Clin Cancer Res 2007; 13:283.
57. Poloso N, Nagarajan S, Bumgarner GW, Zampell J, Selvaraj P. Designer cancer vaccines made easy: protein transfer of immunostimulatory molecules for use in therapeutic tumor vaccines. Front Biosci 2001; 6:D760-75.
58. Singh NP, Miller RW, Yolcu ES, Kilinc MO, Oechsli M, Huseby R, Taylor DD, Perry MT, Larocca RV, Shirwan H. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for induction of auutologous T cell immune response ex vivo. Hum Gene Ther 2006; 17:334.
59. Cimino AM, Palaniswami P, Kim AC, Selvaraj P. Cancer Vaccine Development: Protein Transfer of Membrane-anchored Cytokines and Immunostimulatory Molecules. Immunol Res 2004; 29:231.
60. Nagarajan S, Selvaraj P. Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res 2002; 62:2869.